Cristal Therapeutics
cristaltherapeutics.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$20.3M
2 rounds on record
Latest round
$13.8M
Venture round · Jan 2017 · 9 yr ago
Team
51-200
employees, estimated range
Backers
1
LIOF
The money's age
Long since its last round
116 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 19, 2017
Raised a round Venture round $13.8M · led by Aglaia BioMedical Ventures · FinanzNachrichten.de
Apr 23, 2015
New executive Cristal Therapeutics Announces Appointment Of Jeroen Tonnaer As Chief Business Officer · fiercebiotech.com
Dec 15, 2014
Raised a round Venture round $6.5M · PE Hub
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jan 2017 | $13.8M | Aglaia BioMedical Ventures lead | FinanzNachrichten.de |
| Venture round | Dec 2014 | $6.5M | — | PE Hub |
Backed byfrom the funds' portfolios and accelerator catalogs
LIOF Investors in similar startupsfunds that back the companies most like this one
backs Still Bright
backs Scilife
backs Revisto
backs Algorithmiq
backs Algorithmiq
backs Still Bright
Similar startupsby what they do, their industry and backers
Discngine is a software company that provides software and services for life science research informatics. Its flagship product is Ideation…
Europa Biosite is a leading European distributor of life science products, dedicated to raising the standards of life science distribution.
Sironix Renewables delivers high-performing surfactants that meet the formulation demands of today’s eco-friendly cleaning and personal…
Cold Chain Technologies is a provider of insulated packaging solutions ensuring product safety for the life sciences industry.
Reshaping healthcare and life sciences with quantum computing.
Powering a faster, cleaner, and more abundant copper supply. We’ve transformed copper extraction with localized, cost-effective technology…
News
Intravacc, Cristal Therapeutics Collaborate on Novel Vaccine Platforms Pharmaceutical Technology
Intravacc and Cristal Therapeutics have entered into a strategic collaboration for the development of novel vaccine programs against human diseases.
Read more
Report
From discovery to delivery: CliCr-enabled Cas9-siRNA conjugates for advanced gene editing
A recent publication by CliCr inventor Matt Timmers describes an engineered SpCas9 platform bearing azide handles, enabling site-specific CliCr conjugation of siRNA while preserving both Cas9 editing and siRNA silencing activity. By applying the same CliC
Read more
Report
CliCr: site-specific peptide functionalisation during SPPS
CliCr enables site-specific incorporation of clickable handles directly during SPPS, overcoming the cleavage instability that limits traditional SPAAC reagents. Built on TMTHSI, CliCr gives peptide teams precise positional control and robust compatibility
Read more
Report
Curapath and Cristal Therapeutics sign co-exclusive license of CliCr bioconjugation platform
Paterna, Valencia, SPAIN and Maastricht, THE NETHERLANDS - 26 November 2025, Curapath, a leading innovator in the development and manufacturing of polymer and lipid-based drug delivery systems, and Cristal Therapeutics, a biotech company developing innova
Read more
Report
Cristal Therapeutics and TBD Pharmatech enter exclusive supply agreement for CliCr conjugation reagents
Key Highlights: Exclusive Partnership: TBD Pharmatech will be the sole supplier of CliCr to Cristal Therapeutics. Strategic Supply Security: The agreement secures a robust and high-quality supply of CliCr for Cristal's and its clients pipelines Commitment
Read more
Report
Cristal Therapeutics signs non-exclusive license of CliCr bioconjugation platform with Sapreme Technologies
Maastricht, The Netherlands - 11 September 2025 Cristal Therapeutics, a biotech company developing innovative conjugation technologies, today announced it has entered into a non-exclusive license agreement with Sapreme Technologies. The agreement allows S
Read more
Report
CliCr and CliCr derivatives are available via Iris Biotech GmbH
As per 25 Jan 2023, Iris Biotech sells CliCr and CliCr reagents for non-GXP research purposes. For GXP applications, parties are to connect with Cristal Therapeutics. Read more information on https://www.iris-biotech.de/de/blog/potm-clicrr-an-innovative-c
Read more
Report
Cristal Therapeutics to collaborate with Lonza on CliCr
20230117 Lonza collaborates with Cristal Therapeutics "CliCr is a powerful metal-free click chemistry technology for the life science industry which offers shorter reaction times and greater yields and hence attractive CoG than comparative reagents on the
Read more
Report
New Data Opens Potential for Patient Stratification for CriPec Nanomedicines in Cancer and Other Indications via Non- Invasive Imaging
Maastricht, The Netherlands, 4 May 2022 - Cristal Therapeutics, a Dutch pharmaceutical company developing tailored nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the publication of the results of
Read more
Report
BIO Digital
June 14-17 2021 BIO Digital Digital The post BIO Digital appeared first on Cristal Therapeutics.
Read more
Report
Show more news